^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Seq-MRD® assay

Type:
CE Marked
Related tests:

Details

Evidence
The Seq-MRD® assay has been optimized with Genetron’s One-step Seq technology, which enables the DNA library construction process for gene sequencing to finish with a single PCR reaction and minimizes the risks of contamination and false positive results. This simple operational feature, together with Genetron’s fully automated bioinformatics solutions, enables Seq-MRD® to achieve high throughput and accuracy, good uniformity, high cost-efficiency, and fast turnaround times, when compared with traditional detection methods. To date, Seq-MRD® has been tested with thousands of samples of ALL, MM, and CLL in China.
Cancer:
B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma
Gene:
IGH (Immunoglobulin Heavy Locus), IGK (Immunoglobulin Kappa Locus)
Method:
Next-Generation Sequencing (NGS)
Approvals
Date
Cancer
Gene
Drug
By
04/19/22
CE